| Title |
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
|
|---|---|
| Published in |
Journal of Clinical Oncology, July 2013
|
| DOI | 10.1200/jco.2013.49.3122 |
| Pubmed ID | |
| Authors |
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F. Col, Jack Cuzick, Nancy E. Davidson, Andrea DeCensi, Carol Fabian, Leslie Ford, Judy Garber, Maria Katapodi, Barnett Kramer, Monica Morrow, Barbara Parker, Carolyn Runowicz, Victor G. Vogel, James L. Wade, Scott M. Lippman |
| Abstract |
To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 28% |
| United Kingdom | 2 | 11% |
| India | 2 | 11% |
| France | 1 | 6% |
| Serbia | 1 | 6% |
| Argentina | 1 | 6% |
| Unknown | 6 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 44% |
| Practitioners (doctors, other healthcare professionals) | 6 | 33% |
| Scientists | 3 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 219 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Germany | 2 | <1% |
| Ecuador | 2 | <1% |
| Pakistan | 1 | <1% |
| Portugal | 1 | <1% |
| United Kingdom | 1 | <1% |
| Brazil | 1 | <1% |
| Denmark | 1 | <1% |
| Canada | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 207 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 14% |
| Student > Master | 27 | 12% |
| Other | 23 | 11% |
| Student > Ph. D. Student | 18 | 8% |
| Student > Bachelor | 17 | 8% |
| Other | 62 | 28% |
| Unknown | 41 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 109 | 50% |
| Agricultural and Biological Sciences | 18 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 6% |
| Biochemistry, Genetics and Molecular Biology | 8 | 4% |
| Nursing and Health Professions | 5 | 2% |
| Other | 19 | 9% |
| Unknown | 47 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 113. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2021.
All research outputs
#376,863
of 26,017,215 outputs
Outputs from Journal of Clinical Oncology
#709
of 22,362 outputs
Outputs of similar age
#2,542
of 209,381 outputs
Outputs of similar age from Journal of Clinical Oncology
#9
of 223 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,362 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 209,381 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.